Walbert Keli 4
4 · Apellis Pharmaceuticals, Inc. · Filed Jan 10, 2025
Insider Transaction Report
Form 4
Walbert Keli
Director
Transactions
- Award
Stock Option (Right to Buy)
2025-01-08$33.00/sh+15,388$507,804→ 15,388 totalExercise: $33.00Exp: 2032-01-08→ Common Stock (15,388 underlying) - Award
Common Stock
2025-01-08+9,090→ 9,090 total
Footnotes (2)
- [F1]This restricted stock unit was granted on January 8, 2025. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to her continued service as a director, or upon later termination of her service as a director at her election.
- [F2]This represents a stock option award granted January 8, 2025 that vest 1/3rd per year over a three-year period subject to continued service.